Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Boehringer Drug Combination Showed Response at 12 Weeks in Study

Don't Miss Out —
Follow us on:

Nov. 7 (Bloomberg) -- Boehringer Ingelheim GmbH said 76 percent of patients taking an interferon-free combination of two experimental drugs with ribavirin had a virological response after 12 weeks in a mid-stage study.

The data from an interim analysis of the Sound-C2 trial, which tested drugs BI201335 and BI207127, was presented today at the American Association for the Study of Liver Disease meeting in San Francisco.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.